文献速递淋巴瘤

慢性淋巴细胞白血病患者SARS-CoV-2疫苗的体液和细胞免疫原性:一项前瞻性队列研究

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.
PubMed 文献 · Blood Adv · 2022-01-01

这项前瞻性队列研究纳入接受SARS-CoV-2疫苗和PCV13疫苗(非同时接种)的慢性淋巴细胞白血病(CLL)患者,主要队列为未接受治疗的成人CLL患者。60%(18/30)患者对SARS-CoV-2疫苗产生血清学应答,未治疗患者中绝对淋巴细胞计数≤24 000/µL与血清学应答相关(94% vs 14%;P < .001)。80%(16/20)患者有功能性刺突特异性T细胞应答,包括78%(7/9)RBD免疫测定阴性者。

要点

  • 60%(18/30)CLL患者对SARS-CoV-2疫苗产生血清学应答,未治疗患者中应答更常见(72%)。
  • 未治疗患者中绝对淋巴细胞计数≤24 000/µL与血清学应答相关(94% vs 14%;P < .001)。
  • 80%(16/20)患者有功能性刺突特异性T细胞应答,包括78%(7/9)RBD免疫测定阴性者。

核心结论

  • SARS-CoV-2疫苗接种在CLL患者中诱导功能性T细胞和抗体应答,为研究这些应答的分子机制和临床获益提供了框架。

研究设计与样本

  • 前瞻性队列研究,纳入接受SARS-CoV-2疫苗和PCV13疫苗(非同时接种)的CLL患者,主要队列为未接受治疗的成人CLL患者。
  • 共同主要结局为对SARS-CoV-2(受体结合域[RBD]免疫测定)和PCV13疫苗(23血清型IgG测定)的血清学应答,并表征SARS-CoV-2抗体及其功能活性和评估功能性T细胞应答。
  • 试验注册于www.clinicaltrials.gov,注册号#NCT05007860。

主要发现

  • 60%(18/30)患者对SARS-CoV-2疫苗接种显示血清学应答,未治疗患者中更常见(72%)。
  • 未治疗患者中,绝对淋巴细胞计数≤24 000/µL与血清学应答相关(94% vs 14%;P < .001)。
  • 干扰素-γ释放试验中,80%(16/20)患者有功能性刺突特异性T细胞应答,包括78%(7/9)RBD免疫测定阴性者,该组富含既往接受B细胞耗竭治疗者。
  • 基于珠的多重免疫测定在所有受检患者中鉴定出针对野生型和变异株SARS-CoV-2(α、β、γ和δ)的抗体,并证实这些抗体的Fc受体结合和效应功能。
  • 11例接种后RBD免疫测定阴性患者中,6例(55%)对额外mRNA疫苗剂量有应答;PCV13血清学应答率为29%(8/28)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukemia (CLL), the most common leukemia worldwide, is associated with increased COVID-19 mortality. Previous studies suggest only a portion of vaccinated CLL patients develop severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike antibodies. Whether the elicited antibodies are functional and/or accompanied by functional T-cell responses is unknown. This prospective cohort study included patients with CLL who received SARS-CoV-2 and PCV13 vaccines (not concurrently). The primary cohort included adults with CLL off therapy. Coprimary outcomes were serologic response to SARS-CoV-2 (receptor binding domain [RBD] immunoassay) and PCV13 vaccines (23-serotype IgG assay). Characterization of SARS-CoV-2 antibodies and their functional activity and assessment of functional T-cell responses was performed. Sixty percent (18/30) of patients demonstrated serologic responses to SARS-CoV-2 vaccination, appearing more frequent among treatment-naïve patients (72%). Among treatment-naïve patients, an absolute lymphocyte count ≤24 000/µL was associated with serologic response (94% vs 14%; P < .001). On interferon-γ release assays, 80% (16/20) of patients had functional spike-specific T-cell responses, including 78% (7/9) with a negative RBD immunoassay, a group enriched for prior B-cell-depleting therapies. A bead-based multiplex immunoassay identified antibodies against wild-type and variant SARS-CoV-2 (α, β, γ, and δ) in all tested patients and confirmed Fc-receptor binding and effector functions of these antibodies. Of 11 patients with negative RBD immunoassay after vaccination, 6 (55%) responded to an additional mRNA-based vaccine dose. The PCV13 serologic response rate was 29% (8/28). Our data demonstrate that SARS-CoV-2 vaccination induces functional T-cell and antibody responses in patients with CLL and provides the framework for investigating the molecular mechanisms and clinical benefit of these responses. This trial was registered at www.clinicaltrials.gov as #NCT05007860.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Haydu JE, Maron JS, Redd RA, et al. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Adv. 2022. PMID: 35073571. doi:10.1182/bloodadvances.2021006627

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。